Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Investment analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Cullinan Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($3.24) for the year, up from their prior forecast of ($3.45). HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2026 earnings at ($0.79) EPS, Q1 2027 earnings at ($0.81) EPS, Q2 2027 earnings at ($0.84) EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at ($0.84) EPS and FY2027 earnings at $1.00 EPS.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.10.
Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, October 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. Wedbush increased their price target on shares of Cullinan Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 11th. BTIG Research increased their price target on shares of Cullinan Therapeutics from $40.00 to $41.00 and gave the stock a "buy" rating in a research note on Wednesday, October 28th. Finally, TD Cowen raised shares of Cullinan Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.14.
Check Out Our Latest Stock Report on Cullinan Therapeutics
Cullinan Therapeutics Trading Down 2.4%
CGEM stock opened at $9.27 on Wednesday. The company has a market capitalization of $601.81 million, a P/E ratio of -3.02 and a beta of -0.03. The business has a 50 day simple moving average of $15.37 and a 200-day simple moving average of $15.77. Cullinan Therapeutics has a twelve month low of $8.23 and a twelve month high of $23.19.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new stake in shares of Cullinan Therapeutics during the second quarter worth approximately $25,000. GAMMA Investing LLC lifted its holdings in shares of Cullinan Therapeutics by 38.3% during the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock worth $41,000 after purchasing an additional 738 shares during the period. Allworth Financial LP acquired a new stake in shares of Cullinan Therapeutics during the second quarter worth $53,000. Quantbot Technologies LP purchased a new position in Cullinan Therapeutics in the 2nd quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Cullinan Therapeutics in the 3rd quarter valued at $50,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Cullinan Therapeutics
In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the sale, the insider directly owned 158,844 shares of the company's stock, valued at $3,426,265.08. This represents a 4.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is owned by company insiders.
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.